A Phase 4 interventional study of Risperidone 3 mg and Paliperidone Palmitate 50 mg eq. in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 3 sites in Rwanda. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 99th largest by enrollment of the 123 interventional ones that give a count, is one of 5 that started in 2018, is one of 63 in phase 4, and was the 112th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 149th largest by enrollment of the 176 interventional ones that give a count, is one of 4 that started in 2018, is one of 47 in phase 4, and was the 197th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
Drug: Risperidone 3 mg
Participants will receive 50, 75, 100 or 150 mg eq. (\[paliperidone palmitate\] mg equivalent \[to paliperidone\]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
Drug: Paliperidone Palmitate 50 mg eq. · Drug: Paliperidone Palmitate 75 mg eq. · Drug: Paliperidone Palmitate 100 mg eq. · Drug: Paliperidone Palmitate 150 mg eq.
Participants will receive 175, 263, 350 or 525 mg eq. (\[paliperidone palmitate\] mg equivalent \[to paliperidone\]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
Drug: Paliperidone Palmitate 175 mg eq. · Drug: Paliperidone Palmitate 263 mg eq. · Drug: Paliperidone Palmitate 350 mg eq. · Drug: Paliperidone Palmitate 525 mg eq.
Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
Also known as: R092670
Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
Also known as: R092670
Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
Also known as: R092670
Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
Also known as: R092670
Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
Also known as: R092670
Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
Also known as: R092670
Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
Also known as: R092670
Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
Also known as: R092670
Percentage of Participants With Successful Completion of Study Procedures
Percentage of participants with successful completion of study procedures related to diagnosis and outcome measures assessment will be reported.
Time frame: Up to Week 46
Percentage of Participants With Successful Delivery of Risperidone/PP1M/PP3M for the Duration of the Study
Percentage of participants with successful delivery of risperidone/PP1M/PP3M for the duration of the study will be reported.
Time frame: Up to Week 46
Percentage of Participants With Successful Administration of Risperidone/PP1M/PP3M Throughout the Study
Percentage of participants with successful administration of risperidone/PP1M/PP3M throughout the study will be reported.
Time frame: Up to Week 46
Quality of Life as Assessed by World Health Organization Quality of Life Scale Brief Version (WHO QoL-BREF) Total Score
The WHO QoL-BREF is a 25 item scale used to assess the quality of life. All items are rated on a five-point likert scale using response categories such as 1 represents very poor and 5 represents very well with a possible maximum score of 125 and a minimum score of 25.
Time frame: Up to Week 46
Clinician Satisfaction as Assessed by Clinician Satisfaction Rating Scale Score
The Clinician Satisfaction Rating is a 4-item scale. Two items use a Likert scale with a six-point range from 0 (definitively not) to 6 (definitely) and two items are multiple-choice (example, "select all that apply"). The scale will be used to assess the acceptability and/or burden for the provider associated with the study including treatment with long-acting injectables (LAIs).
Time frame: Up to Week 46
Number of Participants Who Met Mini-International Neuropsychiatric Interview (MINI)-MINI Screen and Module K Criteria
The MINI-Screen is a structured and standardized diagnostic interview used to determine the most common psychiatric disorders according to axis I diagnostic and statistical manual of mental disorders-fourth edition text revision (DSM-IV-TR) and the international classification of diseases and related health problems (ICD-10). The MINI-screen will be administered to participants for preselection by a qualified psychiatric professional. If this step is passed, then Module K of MINI will be applied by a medical doctor (preferably a psychiatrist) or a psychologist in order to confirm the diagnosis of schizophrenia and to determine if there are other psychiatric conditions present. Number of participants who met MINI criteria will be assessed.
Time frame: Up to Week 46
Number of Participants Intended to Complete/Attend Next Visit as Assessed by Intent-to-Attend (ITA) Plus Assessment Scale
The ITA-Plus scale is a single Likert scale question with a range of 0 indicates definitely not attending to 6 indicates definitely attending that will be used to estimate the likelihood of completing the study or attending the next visit to provides qualitative feedback on why completion/attendance may not occur. Number of participants intended to complete/attend next visit will be assessed.
Time frame: Up to Week 46
Direct Cost Assessment of Schizophrenia Care as Assessed by Client Service Receipt Inventory (CSRI) Scale Score
The CSRI scale will be used to assess the costs of schizophrenia care for participants, caregivers, and health care providers, especially direct costs.
Time frame: Up to Week 46
Indirect Cost Assessment of Schizophrenia Care as Assessed by Cost Assessment Questionnaire (CAQ)
The CAQ will be used to assess the costs of schizophrenia care for participants, caregivers, and health care providers, especially indirect costs.
Time frame: Up to Week 46
Change From Baseline in Sheehan Disability Scale (SDS) Total Score
SDS will be used to assess the functioning of participants with schizophrenia. It has participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0 (no impairment) - 10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement.
Time frame: Baseline up to Week 46
Number of Participants With Adverse Events (AEs) as a Measure of Safety
Safety will be assessed by AEs along with concomitant medications, past medical history, and demographics of participants who will participate in this study. An adverse event is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the medication. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
Time frame: Up to Week 46
Psychosis as Assessed by Mental Illness With Lay Evidence (SMILE) Scale Score
The Psychosis module of the SMILE will be used to assess the clinical symptoms of schizophrenia. It is a 15-item Likert scale covering questions to describe participants condition like if they have kept the body neat and clean, difficulty in completing routine tasks, talked to themselves etc with answers on a point range of 0 (Never) to 5 (All the time). It uses 7-day recall period. Both the participant and caregiver participant will complete this scale.
Time frame: Up to Week 46
Clinical Global Impression - Severity of Schizophrenia (CGI-SS) Scale Total Score
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (0 indicates none to 7 indicates extreme symptoms).
Time frame: Up to Week 46
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Oct 2018 to primary completion in Dec 2019, 13 months.
Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Risperidone · Paliperidone
Janssen Research & Development, LLC →